Without evidence from clinical trials, clinicians remain uncertain about drug treatment guidelines for depression following SCI. This study examined the efficacy of Venlafaxine HCI for treating sub-clinical symptoms in community-living persons with SCI. Subjects completed a 13 week intervention and were followed for 26 weeks.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Archives of Physical Medicine and Rehabilitation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Disclosure: None disclosed.
© 2012 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.